Adaptive Biotechnologies Corporation

8.60-0.1500-1.71%Vol 1.73M1Y Perf -78.35%
Jun 27th, 2022 16:00 DELAYED
BID8.12 ASK9.14
Open8.75 Previous Close8.75
Pre-Market- After-Market8.60
 - -  - -%
Target Price
14.50 
Analyst Rating
Moderate Buy 1.86
Potential %
68.60 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     45.80
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     48.06
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.06 
Earnings Rating
Market Cap1.22B 
Earnings Date
3rd Aug 2022
Alpha-0.05 Standard Deviation0.18
Beta1.07 

Today's Price Range

8.218.85

52W Range

5.9643.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
19.54%
1 Month
16.20%
3 Months
-31.32%
6 Months
-69.19%
1 Year
-78.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADPT8.60-0.1500-1.71
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.60
0.16
0.21
-
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
66.00
-149.30
-138.80
-117.20
-93.01
RevenueValueIndustryS&P 500US Markets
154.52M
1.09
32.21
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.43-0.44-2.33
Q04 2021-0.43-0.430.00
Q03 2021-0.43-0.406.98
Q02 2021-0.43-0.3518.60
Q01 2021-0.41-0.2929.27
Q04 2020-0.30-0.33-10.00
Q03 2020-0.28-0.273.57
Q02 2020-0.30-0.2613.33
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date3rd Aug 2022
Estimated EPS Next Report-0.41
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.73M
Shares Outstanding142.23K
Shares Float96.33M
Trades Count17.02K
Dollar Volume14.85M
Avg. Volume2.34M
Avg. Weekly Volume3.38M
Avg. Monthly Volume2.00M
Avg. Quarterly Volume1.64M

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock closed at 8.75 per share at the end of the most recent trading day (a 0.57% change compared to the prior day closing price) with a volume of 9.14M shares and market capitalization of 1.22B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 622 people. Adaptive Biotechnologies Corporation CEO is Chad Robins.

The one-year performance of Adaptive Biotechnologies Corporation stock is -78.35%, while year-to-date (YTD) performance is -68.82%. ADPT stock has a five-year performance of %. Its 52-week range is between 5.955 and 43.3968, which gives ADPT stock a 52-week price range ratio of 7.06%

Adaptive Biotechnologies Corporation currently has a PE ratio of -4.50, a price-to-book (PB) ratio of 1.88, a price-to-sale (PS) ratio of 6.74, a price to cashflow ratio of 10.80, a PEG ratio of 2.32, a ROA of -23.77%, a ROC of -30.92% and a ROE of -35.87%. The company’s profit margin is -93.01%, its EBITDA margin is -138.80%, and its revenue ttm is $154.52 Million , which makes it $1.09 revenue per share.

Of the last four earnings reports from Adaptive Biotechnologies Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Adaptive Biotechnologies Corporation’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Adaptive Biotechnologies Corporation is Moderate Buy (1.86), with a target price of $14.5, which is +68.60% compared to the current price. The earnings rating for Adaptive Biotechnologies Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptive Biotechnologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptive Biotechnologies Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.70, ATR14 : 0.72, CCI20 : 200.64, Chaikin Money Flow : 0.04, MACD : -0.05, Money Flow Index : 63.97, ROC : 26.08, RSI : 59.41, STOCH (14,3) : 85.34, STOCH RSI : 1.00, UO : 61.36, Williams %R : -14.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptive Biotechnologies Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (66.67 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
2 (33.33 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
1.67
Strong Buy
1.40

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

CEO: Chad Robins

Telephone: +1 206 659-0067

Address: 1551 Eastlake Avenue East, Seattle 98102, WA, US

Number of employees: 622

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

63%37%

Bearish Bullish

64%36%

Bearish Bullish

63%37%

TipRanks News for ADPT

Tue, 24 May 2022 12:47 GMT Adaptive Biotechnologies (ADPT) Gets a Hold Rating from Goldman Sachs

- TipRanks. All rights reserved.

News

Stocktwits